Skip to Main Content

Current Clinical Trials

Breast

Title Status

Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Principal Investigator: Michael Wahl, MD

Click here for more information on this trial.


Lung

Title Status

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Nivolumab After Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (ANVIL)

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Principal Investigator: Michael Wahl, MD

Click here for more information on this trial.

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

A Phase 3 Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab

Principal Investigator: David Hufnagel, DO

Hematology

Disease Site Title Status
Myelofibrosis and Essential Thrombocythemia

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Principal Investigator: Ike Onwere, MD

Click here for more information on this trial.
Paroxysmal Nocturnal Hemoglobynuria

Study to Evaluate the Efficacy and Safety of APL-2 in Patients with PNH

Principal Investigator: Farnoush Abar, MD

Click here for more information on this trial.
Multiple Myeloma

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Principal Investigator: Farnoush Abar, MD

Click here for more information on this trial.


Other

Disease Site Title Status
Advanced Cancers

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Principal Investigator: Wei Bai, MD

Click here for more information on this trial.
Bladder

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.
Head and neck

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

Principal Investigator: David Hufnagel, DO

Click here for more information on this trial.

To learn more about cancer clinical trials available, visit clinicaltrials.gov.

 

Disease Site Title Status
Patients with Heart Failure, but Preserved Ejection Fraction

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Principal Investigator: Sridhar Vijayasekaran, MD

Click here for more information on this trial.
Patients not responding to Cardiac Resynchronization Therapy

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing (MORE-CRT MPP)

Principal Investigator: Jeff Hsing, MD

Click here for more information on this trial.
PUMA-NER-6201: A Study Looking at the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide
PUMA-NER-6201: A Study Looking at the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and L

 

Disease Site Title Status
Invasive Fungal Infections Registry (Not a treatment trial)

Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles

Principal Investigator: Sugat Patel, MD

Click here to learn more about this trial.
Disease Site Title Status
Ankylosing Spondylitis

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Principal Investigator: Jonathan Jones, MD

Click here for more information on this trial.

 

Condition Title Status
Insulin Sensitivity, Obesity and Sedentary Lifestyle

Exercise and Insulin Signaling in Human Skeletal Muscle

Samaritan Health Services Principal Investigators: Craig Graham, MD, Nicholas Phillips, MD, and Josh Lenhof, DO


Oregon State University Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, PhD

Click here for more information on this trial or review an informational flyer.

For more information about clinical research at Samaritan, contact us at 541-768-4352 or clinicalresearch@samhealth.org.